Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simultaneous HPV and HBV Vaccination (TANGO)
NCT01082861Phase 4Terminated
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Sep 2010
- Primary completion
- Apr 2011
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
01
Overview
Phase 4, randomised, open-label trial of human papillomavirus type 16 L1 capsid protein antigen and Hepatitis B vaccine in human papillomavirus infection and hepatitis B (HBV) (3 arms), sponsored by National Institute for Public Health and the Environment. Primary endpoint: Antibody seroprotection proportion for HBV at Month 7. Started Sep 2010; status: terminated.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigenHepatitis B vaccine
03
Conditions
human papillomavirus infectionhepatitis B (HBV)
Beyond the preview
Go deeper on NCT01082861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01082861.